Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects Under Seizure and Normal Conditions

NCT02724423 is registered in ClinicalTrials.gov with Neurelis, Inc. as lead sponsor.

NCT NCT02724423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02724423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects Under Seizure and Normal Conditions
Lead sponsor
Neurelis, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2016
Completion date
September 10, 2019
Enrollment
57 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute repetitive seizures